Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Impact · against what's priced in

WVE-007's Phase 1 data provides a significant catalyst by demonstrating fat loss similar to GLP-1s without the associated muscle loss and with a potential for once or twice-yearly dosing. These results position the drug as a potentially best-in-class obesity treatment with a superior tolerability profile compared to current market leaders.

WVE+0.80

No priced-in read yet